Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(2): 80-84
DOI: 10.1055/s-2004-830536
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

The Effect of Short-Term Glycemic Regulation with Gliclazide and Metformin on Postprandial Lipemia

R. Emral1 , O. Köseoğluları1 , V. Tonyukuk1 , A. R. Uysal1 , N. Kamel1 , D. Çorapçıoğlu1
  • 1Ankara University, School of Medicine, Department of Endocrinology and Metabolic Diseases, Ankara, Turkey
Further Information

Publication History

Received: November 20, 2003 First decision: February 12, 2004

Accepted: September 9, 2004

Publication Date:
17 March 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Aim: Exaggerated postprandial lipemia is now accepted as an independent risk factor in atherogenesis in type 2 diabetes mellitus. We investigated if better glycemic control improves fasting and postprandial lipid profile in type 2 diabetic patients in the short-term.

Methods: Thirty-two type 2 diabetic patients were studied before and after desired glycemic regulation with gliclazide and metformin. Basal levels of glucose, total cholesterol, high density lipoprotein, low density lipoprotein, triglyceride, insulin, and C-peptide were evaluated at fasting state. Afterwards, patients were given a standard 400-kcal mixed meal as a breakfast, contaning 35 % fat. At the 2nd and the 4th hours after the breakfast, postprandial glucose, triglyceride, insulin, and C-peptide levels were determined again.

Results: Significant decrease was observed in total cholesterol levels after better glycemic regulation (p < 0.05). Besides, triglyceride levels decreased significantly from 175.36 ± 17.85 mg/dl to 138.73 ± 14.93 mg/dl at fasting state (p < 0.05), from 197.26 ± 20.85 mg/dl to 154.15 ± 14.61 mg/dl at the 2nd hour after mixed meal (p < 0.05), and from 209.63 ± 28.54 mg/dl to 155.63 ± 15.68 mg/dl (p < 0.05) at the 4th hour after the mixed meal, when better glycemic profile was provided. Area under curve for triglyceride levels decreased significantly with the better glycemic regulation (p < 0.01).

Conclusions: Improved glycemic regulation can lower the raised fasting and postprandial triglyceride levels which are important atherosclerotic risk factors in diabetic patients even in short-term. Since this improvement in triglyceride levels comes early, diabetic patients can be evaluated for fasting and postprandial triglyceride levels in the first month of therapy.

Key words

Diabetes mellitus - postprandial lipidemia

References

  • 1 Attia N, Durlach V, Roche D, Paul J L, Soni T, Zahouani A, Landron F, Labrousse F, Leutenegger M, Girard-Globa A. Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment.  Eur J Clin Invest. 1997;  27 55-63
    CrossrefPubMedGoogle Scholar
  • 2 Bierman E L. Atherogenesis in diabetes.  Aterioscler Thromb. 1992;  12 647-656
    PubMedGoogle Scholar
  • 3 Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effect of short- and long-term simvastatin treatment.  Circulation. 2002;  106 1211-1218
    Google Scholar
  • 4 Chen Y-DI, Reaven G M. Intestinally derived lipoproteins: metabolism and clinical significance.  Diabetes Metab Rev. 1991;  7 191-208
    PubMedGoogle Scholar
  • 5 DECODE Study Group . Consequences of the new diagnostic criteria for diabetes in older men and women (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe).  Diabetes Care. 1999;  22 1667-1671
    PubMedGoogle Scholar
  • 6 Donahue R P, Orchard T J. Diabetes mellitus and macrovascular complications: An epidemiological perspective.  Diabetes Care. 1992;  15 1141-1155
    PubMedGoogle Scholar
  • 7 Durlach V. Postprandial lipemia in diabetes. How? Why?.  Diabetes Metab. 1995;  21 112-117
    PubMedGoogle Scholar
  • 8 Evans M, Anderson R A, Graham J, Ellis G R, Morris K, Davies S, Jackson S K, Lewis M J, Frenneaux M P, Rees A. Clofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.  Circulation. 2000;  101 1773-1779
    PubMedGoogle Scholar
  • 9 European Diabetes Epidemiology Group . Comment in Lancet: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe.  Lancet. 1999;  354 617-621
    CrossrefPubMedGoogle Scholar
  • 10 Friedewald W T, Levy R I, Fredericson S. Estimation of the concentration of low lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
    CrossrefPubMedGoogle Scholar
  • 11 Fontbonne A, Eschwege E, Cambien F, Richard J L, Ducimetiere P, Thibult N, Warnet J M, Claude J R, Rosselin G E. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes.  Diabetologia. 1989;  32 300-304
    CrossrefPubMedGoogle Scholar
  • 12 Jeppesen J, Hollenbeck C B, Zhou M-Y. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity and postprandial lipemia.  Atherioscler Thromb Vasc Biol. 1995;  15 320-324
    PubMedGoogle Scholar
  • 13 Jeppesen J, Zhou M Y, Reaven G M. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.  Diabetes Care. 1994;  17 1093-1099
    PubMedGoogle Scholar
  • 14 Kumar N, Dey C S. Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells.  J Exp Biol. 2002;  205 3739-3746
    PubMedGoogle Scholar
  • 15 Lewis G F, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes.  Endocr Rev. 2002;  23 201-229
    CrossrefPubMedGoogle Scholar
  • 16 Maehata E, Yano M, Shiba T, Yamakado M, Inoue M, Suzuki S. Insulin resistance index (HOMA-R method).  Nippon Rinsho. 2002;  8 341-350
    PubMedGoogle Scholar
  • 17 Mero N, Malmstrom R, Steiner G, Taskinen M R, Syvanne M. Postprandial metabolism of apolipoprotein B-48 and B-100 containing particles in type 2 diabetes mellitus:Relations to angiographically verified severity of coronary artery disease.  Atherosclerosis. 2000;  150 167-177
    CrossrefPubMedGoogle Scholar
  • 18 Mero N, Syvanne M, Taskinen M R. Postprandial lipid metabolism in diabetes.  Atherosclerosis. 1998;  141 53-55
    PubMedGoogle Scholar
  • 19 Parks E J. Recent findings in the study of postprandial lipemia.  Curr Atheroscler Rep. 2001;  3 462-470
    CrossrefPubMedGoogle Scholar
  • 20 Patsch J R, Prasada S, Gotto Jr A M, Patsch W. High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase.  J Clin Invest. 1987;  80 341-347
    PubMedGoogle Scholar
  • 21 Reaven G M. Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia.  Diabetes Obes Metab. 2002;  1 13-18
    PubMedGoogle Scholar
  • 22 Ruotolo G, Howard B V. Dyslipidemia of the metabolic syndrome.  Curr Cardiol Rep. 2002;  4 494-500
    PubMedGoogle Scholar
  • 23 Schernthaner G. Improvement of insulin action is an important part of the antidiabetic effect of metformin.  Horm Metab Res Suppl. 1985;  15 116-120
    PubMedGoogle Scholar
  • 24 Skrapari I, Perea D, Ioannidis I, Karabina S A, Elisaf M, Tselepis A D, Karagiannacos P, Katsilambros N. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels.  Diabet Med. 2001;  18 781-785
    CrossrefPubMedGoogle Scholar
  • 25 Taskinen M R. Hyperlipidemia in diabetes.  Ballieres Clin Endocrinol Metab. 1990;  4 743-775
    PubMedGoogle Scholar
  • 26 Vaverkova H. Dyslipoproteinemia and diabetes mellitus.  Vnitr Lek. 2000;  46 532-538
    PubMedGoogle Scholar
  • 27 Weintraub M S, Eisenberg S, Breslow J L. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.  J Clin Invest. 1987;  79 1110-1119
    PubMedGoogle Scholar
  • 28 West K M, Ahuja M M, Bennett P H, Czyzyk A, De Acosta O M, Fuller J H, Grab B, Grabauskas V, Jarrett R J, Kosaka K, Keen H, Krolewski A S, Miki E, Schliak V, Teuscher A, Watkins P J, Strober J A. The role of circulating glucose and triglyceride concentrations and their interactions with other “risk factors” as determinants of arterial disease in nine diabetic population samples from the WHO multinational study.  Diabetes Care. 1983;  6 361-369
    CrossrefPubMedGoogle Scholar
  • 29 Yoshino G, Hirano T, Kazumi T. Dyslipidemia in diabetes mellitus.  Diabetes Res Clin Pract. 1996;  33 1-14
    CrossrefPubMedGoogle Scholar

Dr. Rıfat Emral

İbn-i Sina Hospital, 10th floor, D block

Samanpazarı-06100

Ankara

Turkey

Phone: + 903123094717

Fax: + 90 31 23 09 45 05

Email: rifatemral@hotmail.com

      >